WO2007100182A1 - Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules - Google Patents

Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules Download PDF

Info

Publication number
WO2007100182A1
WO2007100182A1 PCT/KR2006/005047 KR2006005047W WO2007100182A1 WO 2007100182 A1 WO2007100182 A1 WO 2007100182A1 KR 2006005047 W KR2006005047 W KR 2006005047W WO 2007100182 A1 WO2007100182 A1 WO 2007100182A1
Authority
WO
WIPO (PCT)
Prior art keywords
meth
acrylate
buten
polymer
functional groups
Prior art date
Application number
PCT/KR2006/005047
Other languages
French (fr)
Inventor
Hwa Jun Lee
Yong Jin Kim
Joon Chul Cho
Sang Hoon Han
Hak Hee Kang
Original Assignee
Amorepacific Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corporation filed Critical Amorepacific Corporation
Publication of WO2007100182A1 publication Critical patent/WO2007100182A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • GPHYSICS
    • G09EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09BEDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30Anatomical models
    • G09B23/32Anatomical models with moving parts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11Encapsulated compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/06Making microcapsules or microballoons by phase separation
    • B01J13/14Polymerisation; cross-linking
    • GPHYSICS
    • G09EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09BEDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/06Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for physics
    • G09B23/18Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for physics for electricity or magnetism
    • G09B23/182Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for physics for electricity or magnetism for components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/413Nanosized, i.e. having sizes below 100 nm

Definitions

  • the method of preparing the aqueous polymer nanocapsules of the present invention comprises the steps of: (1) polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, and a moiety of functional groups that are capable of inducing a dipole bond with the said compound; and (2) encapsulating the said compound in the hydrophobic polymer of step (1).
  • the present inventors have conducted studies on a method of stabilizing a compound of a molecular weight of 100 ⁇ l,000 having both a disulfide bond and a carboxyl group, especially alpha-lipoic acid, in polymer particles.
  • a method of preparing said polymer nanocapsules comprising the steps of: (1) polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of
  • the said compound of a molecular weight of 100 ⁇ l,000 having both a disulfide bond and a carboxyl group contains specifically alpha-lipoic acid.
  • An initiator used in step (1) is a cationic initiator, examples of which may include azo compounds, such as 2,2'-azobis(N,N'- dimethyleneisobutylamidine)dihydrochloride, 2,2 '-azobis(2- methylpropionamidine)dihydrochloride, 2,2 '-azobis(2- amidinepropane)dihydrochloride, 2,2'-azobis-2-methyl-N-[l,l- bis(hydroxymethyl)-2-hydroxymethyl]propanamide, 2,2'-azobis-2-methyl-N- [l,r-bis-(hydroxymethyl)-ethyl]propanamide, and 2,2'- azobis(isobutylamide)dehydrate.
  • azo compounds such as 2,2'-azobis(N,N'- dimethyleneisobutylamidine)dihydrochloride, 2,2 '-azobis(2- methylpropionamidine)dihydrochloride, 2,2 '-azobis(2- amidine
  • the initiator is preferably used in an amount of about 1 wt% based on the total weight of polymer. If the initiator is used in an amount of less than about lwt%, it does not show an effective initiation effect, and if the initiator is used in an amount of more than about lwt%, it excessively increases the polymerization rate, resulting in a decrease in the stability of the polymerization system.
  • Hydrophobic monomers used in step (1) are radical-polymerizable monomers, examples of which may include styrene, p- or m-methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p- or m-chloromethylstyrene, styrenesulfonic acid, p- or m-t-butoxystyrene, methyl(meth)acrylate, ethyl(meth)acrylate, propyl(meth)acrylate, n-butyl(meth)acrylate, isobutyl(meth)acrylate, t-butyl(meth)acrylate, 2-ethylhexyl(meth)acrylate, n- octyl(meth)acrylate, lauryl(meth)acrylate, stearyl(meth)acrylate, 2- hydroxyethyl(meth
  • Step (2) is a step of encapsulating the compound of step (1) in the hydrophobic polymer of step (1).
  • a method of preparing the nanocapsules according to the present invention can be performed using a general nano precipitation method and comprises:
  • nanocapsules encapsulating alpha-lipoic acid 1O g of the polymer prepared in the foregoing process and 1 g of alpha-lipoic acid were dissolved in 100 ml of ethanol. While 200 ml of distilled water was stirred in a round bottom flask, the mixture of polymer/alpha-lipoic acid/ethanol was added thereto to obtain a self-associated material. From the produced material, ethanol and a small amount of water were evaporated using a rotary evaporator, thus obtaining 50 ml of a polymer nanocapsule.
  • the polymer prepared through the preparation method of Example 1 was a spherical polymer.
  • Example 1 and Comparative Examples 1 and 2 were prepared in the compositions of Table 1 below as a clear gel-type soluble formulation.
  • the formulations had a viscosity of about 4,000 cps, as measured using Brookfield (LVDVII+) at 30 ° C and 12 rpm. [Table 1 ]
  • Formulation 2 and Comparative Formulations 3 and 4 containing said Example 1 and Comparative Examples 1 and 2 were prepared in the compositions of Table 2 below as an opaque gel-type lotion formulation.
  • Each of the oil and aqueous phases was completely dissolved at 70 °C , and emulsified at 7,000 rpm for 5 minutes.
  • the formulation had a viscosity of about 2,500 cps, as measured using Brookfield (L VD VII+) at 30 ° C and 12 rpm.
  • alpha- lipoic acid present in the polymer capsules had excellent stability.
  • alpha- lipoic acid present in the nanocapsules also had excellent stability.
  • the polymer nanocapsules according to the present invention are an excellent double-stabilization system, in which alpha-lipoic acid is encapsulated with the cationic functional groups and the dipole bond inductive functional groups to maintain the chemical structure thereof, and alpha-lipoic acid is prevented from leaking out of the capsules, and protected from an external harmful environment by the polymer matrix.
  • the cationic functional groups and the dipole bond inductive functional groups greatly contributed to the stabilization of alpha-lipoic acid in the formulation, as in the said case of the lotion formulation.
  • the cationic moiety and the dipole bond inductive moiety stabilize the alpha-lipoic acid effectively, and the alpha-lipoic acid in polymer is effectively being protected against water, oil or surfactants in cosmetic formulations.
  • the alpha-lipoic acid shows excellent stability in the formulations, compared to the other systems, because the dipole bond inductive moiety stabilizes the chemical structure of alpha-lipoic acid through the hydrogen bond and the cationic moiety has an increased ability to capture alpha-lipoic acid through ion-ion bond so as to prevent alpha-lipoic acid from leaking out of the capsules.

Abstract

The present invention relates to aqueous polymer nanocapsules stabilizing a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, a method of preparing the same, and an external skin composition containing the same. More particularly, the aqueous polymer nanocapsules of the present invention comprise a compound of a molecular weight of 100-1,000, having both a disulfide bond and a carboxyl group, encapsulated in a hydrophobic polymer, wherein the hydrophobic polymer contains a moiety of cationic functional groups capable of absorbing the said compound, and a moiety of functional groups capable of inducing a dipole bond with the said compound.

Description

[DESCRIPTION] [Invention Title]
POLYMER NANOCAPSULES AND THE PROCESS FOR PREPARING THE SAME, AND THE SKIN EXTERNAL COMPOSITION CONTAINING THE NANOCAPSULES
[Technical Field]
The present invention relates to aqueous polymer nanocapsules stabilizing a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, a method of preparing the same, and an external skin composition containing the same. More particularly, the aqueous polymer nanocapsules of the present invention comprise a compound of a molecular weight of 100-1,000, having both a disulfide bond and a carboxyl group, encapsulated in a hydrophobic polymer. Said hydrophobic polymer contains a moiety of cationic functional groups capable of absorbing the said compound, and a moiety of functional groups capable of inducing a dipole bond with the said compound. The method of preparing the aqueous polymer nanocapsules of the present invention comprises the steps of: (1) polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, and a moiety of functional groups that are capable of inducing a dipole bond with the said compound; and (2) encapsulating the said compound in the hydrophobic polymer of step (1).
[Background Art]
Generally, methods for using polymer particles to stabilize oil-soluble active ingredients are being widely studied. However, encapsulating an oil- soluble active ingredient within a polymer particle is not enough to stabilize an active ingredient completely. Especially, when such particles are used in a cosmetic formulation, the polymer swells through contact with water, surfactant and oil, thereby unstable active ingredients can leak and denature to the outer slowly over a long period of time.
Alpha-lipoic acid is an essential material of metabolism, as it functions as a coenzyme(CoA), which is related to thiamine, in a complete oxidative decarboxylation system such as pyruvic acid or alpha-ketoglutaric acid. Recently, it has been proved that alpha-lipoic acid has an effect on diet and on diabetic treatment, thus it is widely used as a physiological active ingredient. Moreover, the demand for applying to cosmetic is raised due to excellent effects such as skin wrinkle improvement and whitening. However, there are problems in that the alpha-lipoic acid is easily discolored and degraded by contact with external factors such as water, light, and surfactant, and show a decrease in titer, leading to a reduction in effect, and thus the use thereof is extremely limited.
As methods for stabilizing alpha-lipoic acid in formulations to overcome such limitations, PCT/EP02/13346 discloses techniques for stabilizing alpha-lipoic acid in a sodium hydroxide solution, US Patent No. 5,089,269 discloses techniques for stabilizing alpha-lipoic acid using micro particles of 0.1~2000μm that are applied in a gelatin film, US Patent No.
2005-068052 discloses techniques for applying alpha-lipoic acid to an external skin composition containing collagen, and Korean Patent Application No. 2003-0075004 discloses techniques for stabilizing alpha-lipoic acid using cyclodextrin.
However, all of the above methods have limitations in their application to external skin compositions, especially with regard to a peculiar smell due to denaturation of alpha-lipoic acid and stimulation of alpha-lipoic acid itself.
[Disclosure]
[Technical Problem]
Accordingly, the present inventors have conducted studies on a method of stabilizing a compound of a molecular weight of 100~l,000 having both a disulfide bond and a carboxyl group, especially alpha-lipoic acid, in polymer particles. It has thereby been determined that, by preparing a random copolymer by polymerizing a monomer having a moiety of cationic functional groups capable of inducing an ion-ion bond and a moiety of functional groups capable of inducing a dipole bond, and a monomer capable of a barrier function, then preparing an aqueous polymer nanocapsule by encapsulating a compound of a molecular weight of 100-1,000, having both a disulfide bond and a carboxyl group, in said random copolymer, the said compound of a molecular weight of 100-1,000 hiving both a disulfide bond and a carboxyl group can be perfectly stabilized, thereby completing the present invention. Therefore, an object of the present invention is to provide aqueous polymer nanocapsules that are capable of stabilizing perfectly a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group.
Another object of the present invention is to provide a method of preparing said polymer nanocapsules.
Another object of the present invention is to provide an external skin composition containing said polymer nanocapsules. [Description of Drawings]
FIG. 1 is a transmission electron microscope image of polymer nanocapsules containing alpha lipoic acid prepared in Example 1.
[Best Mode]
To achieve the above objects, in an aspect of the present invention, provided are aqueous polymer nanocapsules, comprising a compound of a molecular weight of 100~l,000, having both a disulfide bond and a carboxyl group, encapsulated in a hydrophobic polymer, wherein the hydrophobic polymer contains a moiety of cationic functional groups capable of absorbing the said compound, and a moiety of functional groups capable of inducing a dipole bond with the said compound.
In another aspect of the present invention, provided is a method of preparing said polymer nanocapsules, comprising the steps of: (1) polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of
100-1,000 having both a disulfide bond and a carboxyl group, and a moiety of functional groups that are capable of inducing a dipole bond with the said compound; and (2) encapsulating the said compound in the hydrophobic polymer of step (1).
Hereinafter, the present invention is described in more detail.
The aqueous polymer nanocapsules according to the present invention are a double stabilization system that stabilizes a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, in which an encapsulating capacity is maximized by an ion-ion bond between the carboxyl group inside the said compound and cationic functional groups, and in which the chemical structure is stabilized by functional groups capable of inducing a dipole bond with a disulfide bond inside said compound to block a molecular denaturation, so as to stabilize effectively the compound in the capsules, thereby preventing leakage of the capsules and molecular denaturation, and that further stabilizes the compound in the particles using the outer polymer walls.
Hereinafter, the steps of the inventive preparation method are described in more detail.
Step (1) is a step of polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of 100~l,000 having both a disulfide bond and a carboxyl group, and a moiety of functional groups that are capable of inducing a dipole bond with the said compound.
The said compound of a molecular weight of 100~l,000 having both a disulfide bond and a carboxyl group contains specifically alpha-lipoic acid.
In the present invention, the polymerization of a polymer is conducted using an emulsifier-free emulsion polymerization process.
Monomers having the cationic functional groups used in step (1) are cationic monomers capable of radical polymerization, examples of which may include 2-vinylpyridine, 3-vinylpyridine, 4-vinylpyridine, acrylamide,
(meth)acrylamide, vinylpyrrolidone, vinyl-N-methylpyridinium chloride, 3- methacryloyl-2-ethyl-tetraalkylammonium chloride, methacryloyl-3- hydroxypropyltrimethylammonium chloride, acryloyl-2-ethyl- tetraalkylammonium chloride, acryloyl-3-propyl-tetraalkylammonium chloride, 3-methacryloyl-2-hydroxypropyltrimethylammonium chloride, methacryloyl-3-propyltetraalkylammonium chloride, and (methacryloyl)ethyl dimethylamine. Said monomers having the cationic groups are used in an amount of 0.1-30 mole% based on the total weight of the polymer to be prepared. If the monomers having the cationic groups are used in an amount of less than 0.1 mole %, water-dispersible nanoparticles are not formed, and if used in an amount of more than 30 mole %, the monomers are dispersed to an external water phase during polymerization, resulting in a decrease in yield.
An initiator used in step (1) is a cationic initiator, examples of which may include azo compounds, such as 2,2'-azobis(N,N'- dimethyleneisobutylamidine)dihydrochloride, 2,2 '-azobis(2- methylpropionamidine)dihydrochloride, 2,2 '-azobis(2- amidinepropane)dihydrochloride, 2,2'-azobis-2-methyl-N-[l,l- bis(hydroxymethyl)-2-hydroxymethyl]propanamide, 2,2'-azobis-2-methyl-N- [l,r-bis-(hydroxymethyl)-ethyl]propanamide, and 2,2'- azobis(isobutylamide)dehydrate. The initiator is preferably used in an amount of about 1 wt% based on the total weight of polymer. If the initiator is used in an amount of less than about lwt%, it does not show an effective initiation effect, and if the initiator is used in an amount of more than about lwt%, it excessively increases the polymerization rate, resulting in a decrease in the stability of the polymerization system.
Monomers having the functional groups capable of inducing a dipole bond used in step(l) are radical-polymerizable monomers, examples of which may include 1 -vinyl cyclohexanol, 3-buten-l-ol, 3-buten-2-ol, 2-methyl-3- buten-1-ol, 2-methyl-3-buten-2-ol, l-(2-chloro-phenyl)-3-buten-l-ol, l-(2- methoxyphenyl)-3-buten- 1 -ol, 1 -(4-methoxy-phenyl)-3-buten- 1 -ol, 2- hydroxy ethyl methacrylate, 3-chloro-2-hydroxypropyl methacrylate, 2- hydroxyethyl acrylate, hydroxypropyl acrylate and 4-hydroxybutyl acrylate. Said monomers having the dipole inductive functional groups are used in an amount of 0.1-30 mole% based on the total weight of the polymer to be prepared. This is for inducing a dipole bond with a disulfide bond of a compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group, by encapsulating 1 : 1 based on the equivalent weight of the cationic functional groups moiety, so as to stabilize the said compound. Hydrophobic monomers used in step (1) are radical-polymerizable monomers, examples of which may include styrene, p- or m-methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p- or m-chloromethylstyrene, styrenesulfonic acid, p- or m-t-butoxystyrene, methyl(meth)acrylate, ethyl(meth)acrylate, propyl(meth)acrylate, n-butyl(meth)acrylate, isobutyl(meth)acrylate, t-butyl(meth)acrylate, 2-ethylhexyl(meth)acrylate, n- octyl(meth)acrylate, lauryl(meth)acrylate, stearyl(meth)acrylate, 2- hydroxyethyl(meth)acrylate, polyethyleneglycol(meth)acrylate, methoxypolyethyleneglycol(meth)acrylate, glycidyl(meth)acrylate, dimethylaminoethyl(meth)acrylate, diethylaminoethyl(meth)acrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl ether, allyl butyl ether, allyl glycidyl ether, alkyl(meth)acrylamide and (meth)acrylonitrile. Said hydrophobic monomers are used in an amount of 0.1-50 mole% based on the total weight of the polymer to be prepared.
Step (2) is a step of encapsulating the compound of step (1) in the hydrophobic polymer of step (1).
A method of preparing the nanocapsules according to the present invention can be performed using a general nano precipitation method and comprises:
Dissolving a compound of a molecular weight of 100-1,000, having both a disulfide bond and a carboxyl group, in an amount of 0.01-90mole% based on the total weight of aqueous polymer nanocapsules, and the hydrophobic polymer prepared in step (1), in a suitable organic solvent, i.e. a highly volatile solvent (generally, alcohol/acetone) that is miscible with water and nontoxic and has a vapor pressure lower than that of water; mixing the aqueous phase with the organic phase by stirring at a suitable rate to induce the self-association of the phases, thus preparing an emulsion; and evaporating the organic phase to prepare nanocapsules present in the aqueous phase.
Herein, the compound of a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group is used in an amount of 0.01~90mole% based on the total weight of the aqueous polymer nanocapsules. The aqueous polymer nanocapsules prepared through said steps (1) and (2) can be contained in an external skin composition. Herein, the aqueous polymer nanocapsules are used in an amount of 0.01~50wt% based on the total weight of the composition.
The external skin composition can be formulated into, for example, skin lotion, milk lotion, massage cream, nourishing cream, pack, gel, essence, lipstick, makeup base, foundation, lotion, ointment, cream, patch and spray, but the scope of the present invention is not limited thereto.
[Mode for Invention] Hereinafter, the present invention is described in further detail with reference to examples. It is to be understood, however, that these examples are for illustrative purposes only and are not to be construed to limit the scope of the present invention.
Example 1
Methylmethacrylate in an amount of 50 mole%, based on the total weight of the polymer, was mixed with (methacryloyl)ethyl diethylamine of 25 mole% and hydroxyethyl methacrylate of 25 mole%. The mixture was added to a 0.5% aqueous solution of 2,2'-azobis(2- methylpropionamidine)dihydrochloride and polymerized at 70 °C for 4 hours in a nitrogen atmosphere with stirring at 250 rpm, thus obtaining a polymer latex. The produced polymer latex was condensed with an Ultrafiltration membrane, heated, and water was removed to obtain a film type. The film was recrystallized with acetone/water to remove unreacted monomers, and condensed again with an Ultrafiltration membrane to obtain a film type, and this process was repeated several times. The resulting material was dried and ground in a vacuum oven, thus obtaining polymer as powder.
To prepare nanocapsules encapsulating alpha-lipoic acid, 1O g of the polymer prepared in the foregoing process and 1 g of alpha-lipoic acid were dissolved in 100 ml of ethanol. While 200 ml of distilled water was stirred in a round bottom flask, the mixture of polymer/alpha-lipoic acid/ethanol was added thereto to obtain a self-associated material. From the produced material, ethanol and a small amount of water were evaporated using a rotary evaporator, thus obtaining 50 ml of a polymer nanocapsule.
Comparative Example 1 Capsules were prepared in the same manner as in Example 1, except that, in the preparation of the polymer, (methacryloyl)ethyl diethylamine as the cationic functional groups was not introduced.
Comparative Example 2 Capsules were prepared in the same manner as in Example 1, except that hydroxyethyl methacrylate as the functional groups capable of inducing dipole bonds was not introduced. Test Example 1
The morphology of the structural polymer nanoparticles prepared in Example 1 was observed with a transmission electron microscope (TEM), and the observation results are shown in FIG. 1.
As shown in FIG 1, it can be seen that the polymer prepared through the preparation method of Example 1 was a spherical polymer.
Formulation 1 and Comparative Formulations 1 and 2 Formulation 1 and Comparative Formulations 1 and 2 containing said
Example 1 and Comparative Examples 1 and 2 were prepared in the compositions of Table 1 below as a clear gel-type soluble formulation. The formulations had a viscosity of about 4,000 cps, as measured using Brookfield (LVDVII+) at 30 °C and 12 rpm. [Table 1 ]
Figure imgf000011_0001
Formulation 2 and Comparative Formulations 3 and 4
Formulation 2 and Comparative Formulations 3 and 4 containing said Example 1 and Comparative Examples 1 and 2 were prepared in the compositions of Table 2 below as an opaque gel-type lotion formulation. Each of the oil and aqueous phases was completely dissolved at 70 °C , and emulsified at 7,000 rpm for 5 minutes. The formulation had a viscosity of about 2,500 cps, as measured using Brookfield (L VD VII+) at 30 °C and 12 rpm.
[Table 2]
Figure imgf000012_0001
Formulation 3 and Comparative Formulations 5 and 6 Formulation 3 and Comparative Formulations 5 and 6 containing said Example 1 and Comparative Examples 1 and 2 were prepared in the compositions of Table 3 below as a cream formulation. The preparation process was the same as in Formulation 2. [Table 3]
Figure imgf000013_0001
Test Example 2
To examine the stability within formulation of the prepared Formulations 1~3 and Comparative Formulations 1~6, each of Formulations
1~3 and Comparative Formulations 1~6 were stored in an oven at room temperature and at 40 "C . After predetermined periods of time, samples were taken, and the amount of the remaining active ingredient in each of the samples was measured using liquid chromatography. The measurement results are shown in Tables 4-6. [Table 4]
Figure imgf000014_0001
[Table 5]
Figure imgf000014_0002
[Table 6]
Figure imgf000015_0001
As can be seen in Table 4 above, in the soluble formulation, alpha- lipoic acid present in the polymer capsules had excellent stability. Further, as can be seen in Table 5 above, in the emulsion suspension formulation, alpha- lipoic acid present in the nanocapsules also had excellent stability. This suggests that the polymer nanocapsules according to the present invention are an excellent double-stabilization system, in which alpha-lipoic acid is encapsulated with the cationic functional groups and the dipole bond inductive functional groups to maintain the chemical structure thereof, and alpha-lipoic acid is prevented from leaking out of the capsules, and protected from an external harmful environment by the polymer matrix.
Also, as can be seen in Table 6, in the cream formulation, the cationic functional groups and the dipole bond inductive functional groups greatly contributed to the stabilization of alpha-lipoic acid in the formulation, as in the said case of the lotion formulation.
As described above, the cationic moiety and the dipole bond inductive moiety stabilize the alpha-lipoic acid effectively, and the alpha-lipoic acid in polymer is effectively being protected against water, oil or surfactants in cosmetic formulations. Also, when the cationic moiety and the dipole bond inductive moiety are introduced together in one structure, the alpha-lipoic acid shows excellent stability in the formulations, compared to the other systems, because the dipole bond inductive moiety stabilizes the chemical structure of alpha-lipoic acid through the hydrogen bond and the cationic moiety has an increased ability to capture alpha-lipoic acid through ion-ion bond so as to prevent alpha-lipoic acid from leaking out of the capsules. Accordingly, in the polymer nanocapsules prepared in Example 1, chemical structure denaturation and desorption of particles to external of alpha-lipoic acid, caused by water or oil in the formulation, was prevented. This is due to the cationic functional groups absorbing alpha-lipoic acid, to the dipole bond inductive functional groups maintaining a chemical bond with a hydrogen bond, and to the polymer matrix walls, and thus an excellent stabilization effect was shown compared to other systems.
[Industrial Applicability]
As described above, the polymer nanocapsules according to the present invention can provide an effective stabilization material that enables initial activity of a compound of a molecular weight of 100~l,000 having both a disulfide bond and a carboxyl group, especially alpha-lipoic acid, to be maintained at the nanometer-sized particle level that can maximize the efficiency of active ingredients. Also, according to the present invention, a process for preparing the polymer nanocapsules for encapsulating a compound a molecular weight of 100-1,000 having both a disulfide bond and a carboxyl group can be significantly simplified.

Claims

[CLAIMS] [Claim 1 ]
Polymer nanocapsules, comprising a compound of a molecular weight of 100-1,000, having both a disulfide bond and a carboxyl group, encapsulated in a hydrophobic polymer; wherein the hydrophobic polymer contains a moiety of cationic functional groups capable of absorbing the said compound, and a moiety of functional groups capable of inducing a dipole bond with the said compound.
[Claim 2] The polymer nanocapsules of Claim 1, wherein the compound of molecular weight of 100-1,000 is alpha-lipoic acid. [Claim 3]
The polymer nanocapsules of Claim 1 , wherein a monomer having the cationic functional groups is a radical-polymerizable cationic monomer selected from the group consisting of 2-vinylpyridine, 3-vinylpyridine, 4- vinylpyridine, acrylamide, (meth)acrylamide, vinylpyrrolidone, vinyl-N- methylpyridinium chloride, 3-methacryloyl-2-ethyl-tetraalkylammonium chloride, methacryloyl-3-hydroxypropyltrimethylammonium chloride, acryloyl-2-ethyl-tetraalkylammonium chloride, aery loy 1-3 -propyl- tetraalkylammonium chloride,
3-methacryloyl-2- hydroxypropyltrimethylammonium chloride, methacryloyl-3- propyltetraalkylammonium chloride, and (methacryloyl)ethyl dimethylamine.
[Claim 4]
The polymer nanocapsules of Claim 3, wherein the cationic monomer is used in an amount of 0.1 -30 mole% based on the hydrophobic polymer.
[Claim 5] The polymer nanocapsules of Claim 1, wherein a monomer having the functional groups capable of inducing a dipole bond is a radical-polymerizable monomer selected from the group consisting of 1 -vinyl cyclohexanol, 3- buten-1-ol, 3-buten-2-ol, 2-methyl-3-buten-l-ol, 2-methyl-3-buten-2-ol, l-(2- chloro-phenyl)-3-buten-l-ol, l-(2-methoxyphenyl)-3-buten-l-ol, l-(4- methoxy-phenyl)-3-buten-l-ol, 2-hydroxyethyl methacrylate, 3-chloro-2- hydroxypropyl methacrylate, 2-hydroxyethyl acrylate, hydroxypropyl acrylate, and 4-hydroxybutyl acrylate.
[Claim 6] The polymer nanocapsules of Claim 5, wherein the monomer having the functional groups capable of inducing a dipole bond is used in an amount of 0.1-30 mole% based on the hydrophobic polymer.
[Claim 7]
The polymer nanocapsules of Claim 1, wherein a hydrophobic polymer monomer is selected from the group consisting of styrene, p- or m- methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p- or m- chloromethylstyrene, styrenesulfonic acid, lactate, glycolide, caprolactone, p- or m-t-butoxystyrene, methyl(meth)acrylate, ethyl(meth)acrylate, propyl(meth)acrylate, n-butyl(meth)acrylate, isobutyl(meth)acrylate, t- butyl(meth)acrylate, 2-ethylhexyl(meth)acrylate, n-octyl(meth)acrylate, lauryl(meth)acrylate, stearyl(meth)acrylate, 2-hydroxyethyl(meth)acrylate, polyethyleneglycol(meth)acrylate, methoxypolyethyleneglycol(meth)acrylate, glycidyl(meth)acrylate, dimethylaminoethyl(meth)acrylate, diethylaminoethyl(meth)acrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl ether, allyl butyl ether, allyl glycidyl ether, alkyl(meth)acrylamide, and (meth)acrylonitrile.
[Claim 8] A method of preparing polymer nanocapsules, comprising the steps of:
(1) polymerizing a hydrophobic polymer having a moiety of cationic functional groups that are capable of absorbing a compound of a molecular weight of 100~l,000 having both a disulfide bond and a carboxyl group, and a moiety of functional groups that are capable of inducing a dipole bond with the said compound; and
(2) encapsulating the said compound in the hydrophobic polymer of step (l).
[Claim 9]
The method of Claim 8, wherein a monomer having the cationic functional groups is a radical-polymerizable cationic monomer selected from the group consisting of 2-vinylpyridine, 3-vinylpyridine, 4-vinylpyridine, acrylamide, (meth)acrylamide, vinylpyrrolidone, vinyl-N-methylpyridinium chloride, 3-methacryloyl-2-ethyl-tetraalkylammonium chloride, methacryloyl-
3-hydroxypropyltrimethylammonium chloride, acryloyl-2-ethyl- tetraalkylammonium chloride, aery loy 1-3 -propyl-tetraalkylammonium chloride, 3 -methacry loy 1-2-hydroxypropy ltrimethylammonium chloride, methacryloyl-3-propyltetraalkylammonium chloride, and (methacry loy l)ethyl dimethylamine.
[Claim 10]
The method of Claim 9, wherein the cationic monomer is used in an amount of 0.1-30 mole% based on the hydrophobic polymer.
[Claim 11] The method of Claim 8, wherein a monomer having functional groups capable of inducing a dipole bond is a radical-polymerizable monomer selected from the group consisting of 1-vinyl cyclohexanol, 3-buten-l-ol, 3- buten-2-ol, 2-methyl-3-buten-l-ol, 2-methyl-3-buten-2-ol, l-(2-chloro- phenyl)-3 -buten- 1 -ol, 1 -(2-methoxyphenyl)-3-buten- 1 -ol, 1 -(4-methoxy- phenyl)-3-buten-l-ol, 2-hydroxy ethyl methacrylate, 3-chloro-2-hydroxypropyl methacrylate, 2-hydroxyethyl acrylate, hydroxypropyl acrylate, and 4- hydroxybutyl acrylate.
[Claim 12]
The method of Claim 11, wherein the monomer having functional groups capable of inducing a dipole bond is used in an amount of 0.1-30 mole% based on the hydrophobic polymer.
[Claim 13]
The method of Claim 8, wherein a hydrophobic polymer monomer is selected from the group consisting of styrene, p- or m-methylstyrene, p- or m- ethylstyrene, p- or m-chlorostyrene, p- or m-chloromethylstyrene, styrenesulfonic acid, lactate, glycolide, caprolactone, p- or m-t-butoxystyrene, methyl(meth)acrylate, ethyl(meth)acrylate, propyl(meth)acrylate, n- butyl(meth)acrylate, isobutyl(meth)acrylate, t-butyl(meth)acrylate, 2- ethylhexyl(meth)acrylate, n-octyl(meth)acrylate, lauryl(meth)acrylate, stearyl(meth)acrylate, 2-hydroxyethyl(meth)acrylate, polyethyleneglycol(meth)acrylate, methoxypolyethyleneglycol(meth)acrylate, glycidyl(meth)acrylate, dimethylaminoethyl(meth)acrylate, diethylaminoethyl(meth)acrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl ether, allyl butyl ether, allyl glycidyl ether, alkyl(meth)acrylamide, and (meth)acrylonitrile.
[Claim 14] The method of Claim 8, wherein the compound of a molecular weight of 100-1,000 is alpha-lipoic acid. [Claim 15] An external skin composition containing the polymer nanocapsules of Claim 1. [Claim 16]
The external skin composition of Claim 15, formulated as one of the group consisting of skin softener, skin lotion, massage cream, nou rishing cream, pack, gel, essence, lipstick, make-up base, foundation, lotion, ointment, gel, cream, patch, and spray.
PCT/KR2006/005047 2006-02-28 2006-11-28 Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules WO2007100182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0019285 2006-02-28
KR1020060019285A KR101262261B1 (en) 2006-02-28 2006-02-28 Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules

Publications (1)

Publication Number Publication Date
WO2007100182A1 true WO2007100182A1 (en) 2007-09-07

Family

ID=38459261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/005047 WO2007100182A1 (en) 2006-02-28 2006-11-28 Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules

Country Status (2)

Country Link
KR (1) KR101262261B1 (en)
WO (1) WO2007100182A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112992A1 (en) * 2015-12-29 2017-07-06 Natura Cosméticos S.A. Composition of butyl methoxydibenzoilmethane, diethylamino hydroxybenzoil hexyl benzoate, ethyl-hexyl salycilate, homosalate and octocrylene nanoencapsulated in a polymeric thin film nanostructure
CN112638351A (en) * 2018-08-31 2021-04-09 株式会社爱茉莉太平洋 Nanocapsule forming emulsified particle and emulsified composition comprising the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100966919B1 (en) * 2007-10-30 2010-06-30 (주)바이오제닉스 Aqueous cosmetic composition comprising coated antioxidant particle and Method for preparing the particle
KR20090014568A (en) * 2007-08-06 2009-02-11 (주)바이오제닉스 Coated alpha-lipoic acid particle, composition comprising the particle and method for preparing the particle
KR102048710B1 (en) * 2013-07-15 2019-11-27 (주)아모레퍼시픽 Biodegradable fructose 1,6-bisphosphate stabilizing capsule, the method for preparing the same, and the cosmetic composition containing the same
WO2020045983A1 (en) * 2018-08-31 2020-03-05 ㈜아모레퍼시픽 Nanocapsules forming emulsion particles and emulsion composition including same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089269A (en) * 1987-11-07 1992-02-18 Shiseido Company Ltd. Cosmetic containing fine soft microcapsules
US6432434B1 (en) * 1999-04-22 2002-08-13 The United States Of America As Represented By The Secretary Of The Army Treatment of and/or prophylaxis against brain and spinal cord injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089269A (en) * 1987-11-07 1992-02-18 Shiseido Company Ltd. Cosmetic containing fine soft microcapsules
US6432434B1 (en) * 1999-04-22 2002-08-13 The United States Of America As Represented By The Secretary Of The Army Treatment of and/or prophylaxis against brain and spinal cord injury

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112992A1 (en) * 2015-12-29 2017-07-06 Natura Cosméticos S.A. Composition of butyl methoxydibenzoilmethane, diethylamino hydroxybenzoil hexyl benzoate, ethyl-hexyl salycilate, homosalate and octocrylene nanoencapsulated in a polymeric thin film nanostructure
CN112638351A (en) * 2018-08-31 2021-04-09 株式会社爱茉莉太平洋 Nanocapsule forming emulsified particle and emulsified composition comprising the same
US20210299008A1 (en) * 2018-08-31 2021-09-30 Amorepacific Corporation Nanocapsules forming emulsion particles and emulsion composition including same

Also Published As

Publication number Publication date
KR101262261B1 (en) 2013-05-08
KR20070089358A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
JP5745856B2 (en) Carotenoid stabilized bilayer polymer capsule, method for producing the same, and cosmetic composition containing the same
EP1304161B1 (en) Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
US8187580B2 (en) Polymeric assisted delivery using separate addition
WO2007100182A1 (en) Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules
EP1937204B1 (en) Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
JP6719456B2 (en) Hybrid perfume microcapsule
KR101272741B1 (en) Cationic polymer nanocapsules for the stabilization of active ingredients and the process for preparing the same, and the cosmetic composition containing the nanocapsules
JP5718815B2 (en) Polymer particles prepared from polymerizable alkylene glycol (meth) acrylate monomers
BR112015010480B1 (en) PARTICULATE, PARTICULAR VEHICLE OF CORE BENEFIT AGENT AND COVERAGE, PRODUCT MANUFACTURING PROCESS, SUBSTRATE TREATMENT METHOD AND HOUSEHOLD OR PERSONAL COMPOSITION
DK2164941T3 (en) A method of formulating aroma-forming substances to protect them and to enhance their residue
KR100836032B1 (en) Multi-hollow polymer microcapsules containing L-ascorbic acid, the process for preparation of the same and the cosmetic composition thereof
KR100825834B1 (en) Thermotropic liquid crystal microcapsules for the stabilization of water-insoluble active ingredients by liquid crystal association stabilization system LASS and the process for preparing the same, and the cosmetic composition containing the microcapsules
KR100581215B1 (en) Flavonoid-deposited polymer composite particles and a process for preparation of the same, and cosmetic compositions containing the same
KR101051557B1 (en) Method for producing polymer microcapsules in which vitamin VII is collected and cosmetic composition containing same
KR20150008731A (en) Biodegradable fructose 1,6-bisphosphate stabilizing capsule, the method for preparing the same, and the cosmetic composition containing the same
KR101193606B1 (en) Cosmetic Composition for Enhancing Skin Penetration Containing pH Responsive Nano Particles and Biomimetic Surfactant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06823755

Country of ref document: EP

Kind code of ref document: A1